Oncogenic protein interfaces: small molecules, big challenges
The DOI matches its Crossref record; 162 of the 162 references it cites were found in a registry or an index.
Abstract
Historically, targeting protein-protein interactions with small molecules was not thought possible because the corresponding interfaces were considered mostly flat and featureless and therefore 'undruggable'. Instead, such interactions were targeted with larger molecules, such as peptides and antibodies. However, the past decade has seen encouraging breakthroughs through the refinement of existing techniques and the development of new ones, together with the identification and exploitation of unexpected aspects of protein-protein interaction surfaces. In this Review, we describe some of the latest techniques to discover modulators of protein-protein interactions and how current drug discovery approaches have been adapted to successfully target these interfaces.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Protein–protein interactions (PPIs) play a crucial role in numerous biological processes, including signal transduction, cell proliferation, growth, differentiation, apoptosis.303–305”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [305]
In the citing paper
“However, their suitability for tight and narrow PPI interfaces and poor selectivity limits their application in targeting PPIs.305”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [305]
In the citing paper
“PPIs have relatively large and amorphous interfaces, rather than small and well-defined crevices.”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [22]
In the citing paper
“Compared with targeting enzymes or receptors, however, the development of molecules targeting PPIs has been challenging [22–24].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [22]
Citations
Cites
AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility
Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009) · Journal of Computational Chemistry · doi:10.1002/jcc.21256 · Cited by 25,486
Thornberry, N. A., & Lazebnik, Y. (1998) · Science · doi:10.1126/science.281.5381.1312 · Cited by 6,887
Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. Cohen
Jones, G., Willett, P., Glen, R. C., Leach, A. R., & Taylor, R. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0897 · Cited by 6,763
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Baell, J. B., & Holloway, G. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901137j · Cited by 3,944
Human Growth Hormone and Extracellular Domain of Its Receptor: Crystal Structure of the Complex
de Vos, A. M., Ultsch, M., & Kossiakoff, A. A. (1992) · Science · doi:10.1126/science.1549776 · Cited by 2,239
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
Discovering High-Affinity Ligands for Proteins: SAR by NMR
Shuker, S. B., Hajduk, P. J., Meadows, R. P., & Fesik, S. W. (1996) · Science · doi:10.1126/science.274.5292.1531 · Cited by 2,041
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
Anatomy of hot spots in protein interfaces
Bogan, A. A., & Thorn, K. S. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.1843 · Cited by 1,988
A Hot Spot of Binding Energy in a Hormone-Receptor Interface
Clackson, T., & Wells, J. A. (1995) · Science · doi:10.1126/science.7529940 · Cited by 1,983
The atomic structure of protein-protein recognition sites 1 1Edited by A. R. Fersht
Conte, L. L., Chothia, C., & Janin, J. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.2439 · Cited by 1,964
Reaching for high-hanging fruit in drug discovery at protein–protein interfaces
Wells, J. A., & McClendon, C. L. (2007) · Nature · doi:10.1038/nature06526 · Cited by 1,960
DOCK 4.0: Search strategies for automated molecular docking of flexible molecule databases
Ewing, T. J. A., Makino, S., Skillman, A. G., & Kuntz, I. D. (2001) · Journal of Computer-Aided Molecular Design · doi:10.1023/a:1011115820450 · Cited by 1,187
A decade of fragment-based drug design: strategic advances and lessons learned
Hajduk, P. J., & Greer, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2220 · Cited by 1,064
Development trends for human monoclonal antibody therapeutics
Nelson, A. L., Dhimolea, E., & Reichert, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3229 · Cited by 1,026
A small molecule inhibitor of β-catenin/cyclic AMP response element-binding protein transcription
Emami, K. H., Nguyen, C., Ma, H., Kim, D. H., Jeong, K. W., Eguchi, M., Moon, R. T., Teo, J.-L., Oh, S. W., Kim, H. Y., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404875101 · Cited by 874
Targeting IAP proteins for therapeutic intervention in cancer
Fulda, S., & Vucic, D. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3627 · Cited by 837
Bellmunt, J., Théodore, C., Demkov, T., Komyakov, B., Sengelov, L., Daugaard, G., Caty, A., Carles, J., Jagiello-Gruszfeld, A., Karyakin, O., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.5534 · Cited by 766
Structure-based prediction of protein–protein interactions on a genome-wide scale
Zhang, Q. C., Petrey, D., Deng, L., Qiang, L., Shi, Y., Thu, C. A., Bisikirska, B., Lefebvre, C., Accili, D., Hunter, T., et al. (2012) · Nature · doi:10.1038/nature11503 · Cited by 723
Convergent Solutions to Binding at a Protein-Protein Interface
DeLano, W. L., Ultsch, M. H., de, A. M., Vos, & Wells, J. A. (2000) · Science · doi:10.1126/science.287.5456.1279 · Cited by 672
Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain
Liu, Z., Sun, C., Olejniczak, E. T., Meadows, R. P., Betz, S. F., Oost, T., Herrmann, J., Wu, J. C., & Fesik, S. W. (2000) · Nature · doi:10.1038/35050006 · Cited by 646
Erlanson, D. A., McDowell, R. S., & O'Brien, T. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm040031v · Cited by 642
Immunotherapy: past, present and future
Waldmann, T. A. (2003) · Nature Medicine · doi:10.1038/nm0303-269 · Cited by 628
Gandhi, L., Camidge, D. R., Ribeiro de Oliveira, M., Bonomi, P., Gandara, D., Khaira, D., Hann, C. L., McKeegan, E. M., Litvinovich, E., Hemken, P. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.6208 · Cited by 603
Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling
Zimmermann, G., Papke, B., Ismail, S., Vartak, N., Chandra, A., Hoffmann, M., Hahn, S. A., Triola, G., Wittinghofer, A., Bastiaens, P. I. H., et al. (2013) · Nature · doi:10.1038/nature12205 · Cited by 596
Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
Ding, Q., Zhang, Z., Liu, J.-J., Jiang, N., Zhang, J., Ross, T. M., Chu, X.-J., Bartkovitz, D., Podlaski, F., Janson, C., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400487c · Cited by 595
Dassie, J. P., Liu, X.-Y., Thomas, G. S., Whitaker, R. M., Thiel, K. W., Stockdale, K. R., Meyerholz, D. K., McCaffrey, A. P., McNamara, J. O., & Giangrande, P. H. (2009) · Nature Biotechnology · doi:10.1038/nbt.1560 · Cited by 589
Towle, M. J., Salvato, K. A., Budrow, J., Wels, B. F., Kuznetsov, G., Aalfs, K. K., Welsh, S., Zheng, W., Seletsky, B. M., Palme, M. H., et al. (2001) · PubMed · Cited by 581
The MIPS mammalian protein–protein interaction database
Pagel, P., Kovac, S., Oesterheld, M., Brauner, B., Dunger-Kaltenbach, I., Frishman, G., Montrone, C., Mark, P., Stümpflen, V., Mewes, H.-W., et al. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bti115 · Cited by 540
Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia
Grembecka, J., He, S., Shi, A., Purohit, T., Muntean, A. G., Sorenson, R. J., Showalter, H. D., Murai, M. J., Belcher, A. M., Hartley, T., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.773 · Cited by 462
Fragment-Based Approaches in Drug Discovery and Chemical Biology
Scott, D. E., Coyne, A. G., Hudson, S. A., & Abell, C. (2012) · Biochemistry · doi:10.1021/bi3005126 · Cited by 460
Lee, F. Y., Borzilleri, R. M., Fairchild, C. R., Kim, S., Long, B. H., Raventós-Suárez, C., Vite, G. D., Rose, W. C., & Kramer, R. A. (2001) · PubMed · Cited by 453
Discovery and Cocrystal Structure of Benzodiazepinedione HDM2 Antagonists That Activate p53 in Cells
Grasberger, B. L., Lu, T., Schubert, C., Parks, D. J., Carver, T. E., Koblish, H. K., Cummings, M. D., LaFrance, L. V., Milkiewicz, K. L., Calvo, R. R., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049137g · Cited by 432
Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity
Schimmer, A. D., Welsh, K., Pinilla, C., Wang, Z., Krajewska, M., Bonneau, M.-J., Pedersen, I. M., Kitada, S., Scott, F. L., Bailly-Maitre, B., et al. (2004) · Cancer Cell · doi:10.1016/s1535-6108(03)00332-5 · Cited by 411
Targeting protein–protein interactions as an anticancer strategy
Ivanov, A. A., Khuri, F. R., & Fu, H. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.04.007 · Cited by 401
Protein–protein interaction and quaternary structure
Janin, J., Bahadur, R. P., & Chakrabarti, P. (2008) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583508004708 · Cited by 398
Discovery of RG7112: a small-molecule MDM2 inhibitor in clinical development
Vu, B., Wovkulich, P., Pizzolato, G., Lovey, A., Ding, Q., Jiang, N., Liu, J.-J., Zhao, C., Glenn, K., Wen, Y., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml4000657 · Cited by 395
Tethering: Fragment-Based Drug Discovery
Erlanson, D. A., Wells, J. A., & Braisted, A. C. (2004) · Annual Review of Biophysics and Biomolecular Structure · doi:10.1146/annurev.biophys.33.110502.140409 · Cited by 385
Structure-guided design of a selective BCL-XL inhibitor
Lessene, G., Czabotar, P. E., Sleebs, B. E., Zobel, K., Lowes, K. N., Adams, J. M., Baell, J. B., Colman, P. M., Deshayes, K., Fairbrother, W. J., et al. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1246 · Cited by 381
Binding of small molecules to an adaptive protein–protein interface
Arkin, M. R., Randal, M., DeLano, W. L., Hyde, J., Luong, T. N., Oslob, J. D., Raphael, D. R., Taylor, L., Wang, J., McDowell, R. S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.252756299 · Cited by 375
Discovery of Potent Antagonists of the Antiapoptotic Protein XIAP for the Treatment of Cancer
Oost, T. K., Sun, C., Armstrong, R. C., Al-Assaad, A.-S., Betz, S. F., Deckwerth, T. L., Ding, H., Elmore, S. W., Meadows, R. P., Olejniczak, E. T., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm040037k · Cited by 366
Origin and evolution of high throughput screening
Pereira, D. A., & Williams, J. A. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707373 · Cited by 364
Dimitrov, D. S. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-921-1_1 · Cited by 347
Latest developments in molecular docking: 2010–2011 in review
Yuriev, E., & Ramsland, P. A. (2013) · Journal of Molecular Recognition · doi:10.1002/jmr.2266 · Cited by 344
Nikolovska-Coleska, Z., Xu, L., Hu, Z., Tomita, Y., Li, P., Roller, P. P., Wang, R., Fang, X., Guo, R., Zhang, M., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030420+ · Cited by 343
Mita, A. C., Denis, L. J., Rowinsky, E. K., DeBono, J. S., Goetz, A. D., Ochoa, L., Forouzesh, B., Beeram, M., Patnaik, A., Molpus, K., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0596 · Cited by 332
Discovery of Small-Molecule Inhibitors of Bcl-2 through Structure-Based Computer Screening
Enyedy, I. J., Ling, Y., Nacro, K., Tomita, Y., Wu, X., Cao, Y., Guo, R., Li, B., Zhu, X., Huang, Y., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010016f · Cited by 315
Discovery of a Potent Inhibitor of the Antiapoptotic Protein Bcl-x L from NMR and Parallel Synthesis
Petros, A. M., Dinges, J., Augeri, D. J., Baumeister, S. A., Betebenner, D. A., Bures, M. G., Elmore, S. W., Hajduk, P. J., Joseph, M. K., Landis, S. K., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0507532 · Cited by 292
Tovar, C., Graves, B., Packman, K., Filipovic, Z., Xia, B. H. M., Tardell, C., Garrido, R., Lee, E., Kolinsky, K., To, K.-H., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2807 · Cited by 283
Clackson, T., Ultsch, M. H., Wells, J. A., & de Vos, A. M. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.1669 · Cited by 278
Lee, E. F., Czabotar, P. E., Smith, B. J., Deshayes, K., Zobel, K., Colman, P. M., & Fairlie, W. D. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402178 · Cited by 278
O'Brien, S. M., Claxton, D. F., Crump, M., Faderl, S., Kipps, T., Keating, M. J., Viallet, J., & Cheson, B. D. (2009) · Blood · doi:10.1182/blood-2008-02-137943 · Cited by 274
Introduction to Fragment-Based Drug Discovery
Erlanson, D. A. (2011) · Topics in Current Chemistry · doi:10.1007/128_2011_180 · Cited by 259
García-Echeverría, C., Chène, P., Blommers, M. J. J., & Furet, P. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990966p · Cited by 246
Peptide modulators of protein–protein interactions in intracellular signaling
Souroujon, M. C., & Mochly-Rosen, D. (1998) · Nature Biotechnology · doi:10.1038/nbt1098-919 · Cited by 221
Transient Pockets on Protein Surfaces Involved in Protein−Protein Interaction
Eyrisch, S., & Helms, V. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070095g · Cited by 213
The Structure of Interleukin-2 Complexed with Its Alpha Receptor
Rickert, M., Wang, X., Boulanger, M. J., Goriatcheva, N., & Garcia, K. C. (2005) · Science · doi:10.1126/science.1109745 · Cited by 212
Phage display systems and their applications
Paschke, M. (2006) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-005-0270-9 · Cited by 208
Shi, A., Murai, M. J., He, S., Lund, G., Hartley, T., Purohit, T., Reddy, G., Chruszcz, M., Grembecka, J., & Cierpicki, T. (2012) · Blood · doi:10.1182/blood-2012-05-429274 · Cited by 204
McMillan, K., Adler, M., Auld, D. S., Baldwin, J. J., Blasko, E., Browne, L. J., Chelsky, D., Davey, D., Dolle, R. E., Eagen, K. A., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.4.1506 · Cited by 201
Schimmer, A. D., O'Brien, S., Kantarjian, H., Brandwein, J., Cheson, B. D., Minden, M. D., Yee, K., Ravandi, F., Giles, F., Schuh, A., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0999 · Cited by 192
Chen, C.-H. B., Chernis, G. A., Hoang, V. Q., & Landgraf, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1332660100 · Cited by 190
A Neutralizing RNA Aptamer against EGFR Causes Selective Apoptotic Cell Death
Esposito, C. L., Passaro, D., Longobardo, I., Condorelli, G., Marotta, P., Affuso, A., de Franciscis, V., & Cerchia, L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024071 · Cited by 182
Structural biology and drug discovery for protein–protein interactions
Jubb, H., Higueruelo, A. P., Winter, A., & Blundell, T. L. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.03.006 · Cited by 181
Liu, G., Kelly, W. K., Wilding, G., Leopold, L., Brill, K., & Somer, B. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2985 · Cited by 181
Expanding the Number of ‘Druggable’ Targets: Non‐Enzymes and Protein–Protein Interactions
Makley, L. N., & Gestwicki, J. E. (2013) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12066 · Cited by 176
Protein–protein interactions and cancer: small molecules going in for the kill
Arkin, M. (2005) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2005.03.001 · Cited by 175
Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth
Mahlknecht, G., Maron, R., Mancini, M., Schechter, B., Sela, M., & Yarden, Y. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1302594110 · Cited by 169
Gang, E. J., Hsieh, Y.-T., Pham, J., Zhao, Y., Nguyen, C., Huantes, S., Park, E., Naing, K., Klemm, L., Swaminathan, S., et al. (2014) · Oncogene · doi:10.1038/onc.2013.169 · Cited by 160
Rational Design of Proteolytically Stable, Cell-Permeable Peptide-Based Selective Mcl-1 Inhibitors
Muppidi, A., Doi, K., Edwardraja, S., Drake, E. J., Gulick, A. M., Wang, H.-G., & Lin, Q. (2012) · Journal of the American Chemical Society · doi:10.1021/ja306864v · Cited by 156
Nucleic acid aptamers: an emerging frontier in cancer therapy
Zhu, G., Ye, M., Donovan, M. J., Song, E., Zhao, Z., & Tan, W. (2012) · Chemical Communications · doi:10.1039/c2cc35042d · Cited by 149
Learning from our mistakes: The ‘unknown knowns’ in fragment screening
Davis, B. J., & Erlanson, D. A. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.03.028 · Cited by 145
Hot-spot mimicry of a cytokine receptor by a small molecule
Thanos, C. D., DeLano, W. L., & Wells, J. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607058103 · Cited by 144
Okamoto, T., Zobel, K., Fedorova, A., Quan, C., Yang, H., Fairbrother, W. J., Huang, D. C. S., Smith, B. J., Deshayes, K., & Czabotar, P. E. (2013) · ACS Chemical Biology · doi:10.1021/cb3005403 · Cited by 136
Small Molecule Inhibitors of the MDM2-p53 Interaction Discovered by Ensemble-Based Receptor Models
Bowman, A. L., Nikolovska‐Coleska, Z., Zhong, H. A., Wang, S., & Carlson, H. A. (2007) · Journal of the American Chemical Society · doi:10.1021/ja073687x · Cited by 128
Peptide-Based Drug Design: Here and Now
Otvos, L. J. (2008) · Methods in molecular biology · doi:10.1007/978-1-59745-419-3_1 · Cited by 128
Identification and Structure of Small‐Molecule Stabilizers of 14–3–3 Protein–Protein Interactions
Rose, R., Erdmann, S., Bovens, S., Wolf, A., Rose, M., Hennig, S., Waldmann, H., & Ottmann, C. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200907203 · Cited by 127
Methods for the Elucidation of Protein-Small Molecule Interactions
McFedries, A., Schwaid, A. G., & Saghatelian, A. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.04.008 · Cited by 126
Winter, A., Higueruelo, A. P., Marsh, M., Sigurdardottir, A., Pitt, W. R., & Blundell, T. L. (2012) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583512000108 · Cited by 126
Metal Impurities Cause False Positives in High-Throughput Screening Campaigns
Hermann, J. C., Chen, Y., Wartchow, C. A., Menke, J. G., Gao, L., Gleason, S. K., Haynes, N.-E., Scott, N., Petersen, A. C., Gabriel, S., et al. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml3003296 · Cited by 125
Czabotar, P. E., Lee, E. F., Thompson, G. V., Wardak, A. Z., Fairlie, W. D., & Colman, P. M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.161281 · Cited by 120
Silvestre, H. L., Blundell, T. L., Abell, C., & Ciulli, A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304045110 · Cited by 119
Experiences in Fragment-Based Lead Discovery
Hubbard, R. E., & Murray, J. B. (2011) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-381274-2.00020-0 · Cited by 116
Potent Small-Molecule Binding to a Dynamic Hot Spot on IL-2
Thanos, C. D., Randal, M., & Wells, J. A. (2003) · Journal of the American Chemical Society · doi:10.1021/ja0382617 · Cited by 116
Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules.
Ngan, V. K., Bellman, K., Panda, D., Hill, B. T., Jordan, M. A., & Wilson, L. (2000) · PubMed · Cited by 112
Hajduk, P. J., Galloway, W. R. J. D., & Spring, D. R. (2011) · Nature · doi:10.1038/470042a · Cited by 111
Inhibitors of the anti-apoptotic Bcl-2 proteins: a patent review
Bajwa, N., Liao, C., & Nikolovska‐Coleska, Z. (2011) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2012.644274 · Cited by 110
Hwang, J. J., Kuruvilla, J., Mendelson, D., Pishvaian, M. J., Deeken, J. F., Siu, L. L., Berger, M. S., Viallet, J., & Marshall, J. L. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0822 · Cited by 109
Targeting Protein–Protein Interactions and Fragment-Based Drug Discovery
Valkov, E., Sharpe, T., Marsh, M., Greive, S., & Hyvönen, M. (2011) · Topics in Current Chemistry · doi:10.1007/128_2011_265 · Cited by 107
Zhao, J., Du, Y., Horton, J. R., Upadhyay, A. K., Lou, B., Bai, Y., Zhang, X., Du, L., Li, M., Wang, B., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1100012108 · Cited by 105
Expanding medicinal chemistry space
Barker, A. J., Kettle, J. G., Nowak, T., & Pease, J. E. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.10.008 · Cited by 104
Gao, M., & Skolnick, J. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117768109 · Cited by 104
Enabling Large-Scale Design, Synthesis and Validation of Small Molecule Protein-Protein Antagonists
Koes, D., Khoury, K., Huang, Y., Wang, W., Bista, M., Popowicz, G. M., Wolf, S., Holak, T. A., Dömling, A., & Camacho, C. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032839 · Cited by 103
Takahashi, S., Reddy, S. V., Chirgwin, J. M., Devlin, R. D., Haipek, C. A., Anderson, J. L., & Roodman, G. D. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)61961-7 · Cited by 102
Phipps, K. D., Surette, A. P., O'Connell, P. A., & Waisman, D. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1748 · Cited by 100
Clinical Applications of the Urokinase Receptor (uPAR) for Cancer Patients
Boonstra, M. C., Verspaget, H. W., Ganesh, S., Kubben, F. J. G. M., Vahrmeijer, A. L., van de Velde, C. J. �., Kuppen, P. J. K., Quax, P. H. A., & Sier, C. F. M. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211796718233 · Cited by 98
Initial testing (stage 1) of LCL161, a SMAC mimetic, by the pediatric preclinical testing program
Houghton, P. J., Kang, M. H., Reynolds, C. P., Morton, C. L., Kolb, E. A., Gorlick, R. G., Keir, S. T., Carol, H., Lock, R. B., Maris, J. M., et al. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.23167 · Cited by 96
Self-citationScreening for GPCR Ligands Using Surface Plasmon Resonance
Navratilova, I. H., Besnard, J., & Hopkins, A. L. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml2000017 · Cited by 95
Smac mimetics: implications for enhancement of targeted therapies in leukemia
Weisberg, E., Ray, A., Barrett, R., Nelson, E., Christie, A. L., Porter, D., Straub, C., Zawel, L., Daley, J. F., Lazo-Kallanian, S., et al. (2010) · Leukemia · doi:10.1038/leu.2010.212 · Cited by 93
Bcl-XL Mutations Suppress Cellular Sensitivity to Antimycin A
Manion, M. K., O’Neill, J., Giedt, C. D., Kim, K. M., Zhang, K. Y. J., & Hockenbery, D. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m306021200 · Cited by 93
In Vitro Selection of RNA Aptamer and Specific Targeting of ErbB2 in Breast Cancer Cells
Kim, M. Y., & Jeong, S. (2011) · Nucleic Acid Therapeutics · doi:10.1089/nat.2011.0283 · Cited by 89
Real, P. J., Cao, Y., Wang, R., Nikolovska-Coleska, Z., Sanz-Ortiz, J., Wang, S., & Fernandez-Luna, J. L. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0945 · Cited by 89
Stabilization and Inhibition of Protein–Protein Interactions: The 14-3-3 Case Study
Milroy, L.-G., Brunsveld, L., & Ottmann, C. (2013) · ACS Chemical Biology · doi:10.1021/cb300599t · Cited by 88
Phase I/II Study of AT-101 with Topotecan in Relapsed and Refractory Small Cell Lung Cancer
Heist, R. S., Fain, J., Chinnasami, B., Khan, W. A., Molina, J. R., Sequist, L. V. D., Temel, J. S., Fidias, P. M., Brainerd, V., Leopold, L. H., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181e8f4dc · Cited by 88
Raimundo, B. C., Oslob, J. D., Braisted, A. C., Hyde, J., McDowell, R. S., Randal, M., Waal, N. D., Wilkinson, J., Yu, C. H., & Arkin, M. R. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049967u · Cited by 86
Discovery of Novel Myc−Max Heterodimer Disruptors with a Three-Dimensional Pharmacophore Model
Mustata, G. I., Follis, A. V., Hammoudeh, D. I., Metallo, S. J., Wang, H., Prochownik, E. V., Lazo, J. S., & Bahar, İ. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801278g · Cited by 85
Virtual high-throughput in silico screening
Seifert, M. H. J., Wolf, K., & Vitt, D. (2003) · BIOSILICO · doi:10.1016/s1478-5382(03)02359-x · Cited by 81
Discovery of a potent and selective Bcl-2 inhibitor using SAR by NMR
Petros, A. M., Huth, J. R., Oost, T. K., Park, C., Ding, H., Wang, X., Zhang, H., Nimmer, P. M., Mendoza, R. R., Sun, C. C., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.09.033 · Cited by 81
Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate
Woll, P. J. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s1526 · Cited by 78
Protein-Protein Interactions and Cancer: Targeting the Central Dogma
L. Garner, A., & D. Janda, K. (2011) · Current Topics in Medicinal Chemistry · doi:10.2174/156802611794072614 · Cited by 77
Discovery of novel inhibitors of Bcl-xL using multiple high-throughput screening platforms
Qian, J., Voorbach, M. J., Huth, J. R., Coen, M. L., Zhang, H., Ng, S., Comess, K. M., Petros, A. M., Rosenberg, S. H., Warrior, U., et al. (2004) · Analytical Biochemistry · doi:10.1016/j.ab.2003.12.034 · Cited by 77
A Leap into the Chemical Space of Protein-Protein Interaction Inhibitors
Villoutreix, B. O., Labbé, C. M., Lagorce, D., Laconde, G., & Spérandio, O. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802651571 · Cited by 74
Inhibitors of the p53/hdm2 protein–protein interaction—path to the clinic
Carry, J., & García-Echeverría, C. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.03.034 · Cited by 73
Discovery of Potent and Selective Benzothiazole Hydrazone Inhibitors of Bcl-XL
Sleebs, B. E., Kersten, W. J. A., Kulasegaram, S., Nikolakopoulos, G., Hatzis, E., Moss, R. M., Parisot, J. P., Yang, H. J., Czabotar, P. E., Fairlie, W. D., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400556w · Cited by 72
Frank, A. O., Feldkamp, M. D., Kennedy, J. P., Waterson, A. G., Pelz, N. F., Patrone, J. D., Vangamudi, B., Camper, D. V., Rossanese, O. W., Chazin, W., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401333u · Cited by 72
Fragment Library Screening and Lead Characterization Using SPR Biosensors
Danielson, U. H. (2009) · Current Topics in Medicinal Chemistry · doi:10.2174/156802609790102392 · Cited by 72
Fischer, P. M., & Lane, D. P. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.04.011 · Cited by 70
Highly Multiplexed Proteomic Platform for Biomarker Discovery, Diagnostics, and Therapeutics
Mehan, M. R., Ostroff, R. M., Wilcox, S. K., Steele, F. R., Schneider, D. J., Jarvis, T. C., Baird, G. S., Gold, L., & Janjić, N. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-4118-2_20 · Cited by 69
Plucking the high hanging fruit: A systematic approach for targeting protein–protein interactions
Raj, M., Bullock, B. N., & Arora, P. S. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.11.023 · Cited by 66
Fragment-Based Screening by Protein Crystallography: Successes and Pitfalls
Chilingaryan, Z., Zhou, Y., & Oakley, A. J. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131012857 · Cited by 66
Chiang, Y., Kuo, C., Wu, Y., Chen, C.-T., Coumar, M. S., Wu, J., Hsieh, H., Chang, C.-Y., Jseng, H.-Y., Wu, M.-H., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801649y · Cited by 63
Drug for an 'undruggable' protein
Baker, N. M., & Der, C. J. (2013) · Nature · doi:10.1038/nature12248 · Cited by 62
Villoutreix, B. O., Bastard, K., Spérandio, O., Fåhræus, R., Poyet, J., Calvo, F. M., Deprez, B. P., & Miteva, M. A. (2008) · Current Pharmaceutical Biotechnology · doi:10.2174/138920108783955218 · Cited by 62
Recent Trends and Observations in the Design of High-Quality Screening Collections
Renner, S., Popov, M., Schuffenhauer, A., ROTH, H. ‐., Breitenstein, W., Marzinzik, A. L., Lewis, I., Krastel, P., Nigsch, F., Jenkins, J. L., et al. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.15 · Cited by 61
Practical Aspects of NMR-Based Fragment Screening
Lepre, C. A. (2011) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-381274-2.00009-1 · Cited by 60
Conlin, A. K., Fornier, M. N., Hudis, C. A., Kar, S., & Kirkpatrick, P. N. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2469 · Cited by 60
Sakkiah, S., Thangapandian, S., John, S., & Lee, K. W. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.04.018 · Cited by 59
Khanna, M., Wang, F., Jo, I., Knabe, W. E., Wilson, S. M., Li, L., Bum‐Erdene, K., Li, J., Sledge, G. W., Khanna, R., et al. (2011) · ACS Chemical Biology · doi:10.1021/cb200180m · Cited by 59
Heeres, J. T., & Hergenrother, P. J. (2010) · Chemical Society Reviews · doi:10.1039/b923660k · Cited by 58
Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases
Flego, M., Ascione, A., Cianfriglia, M., & Vella, S. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-4 · Cited by 57
Fragment approaches in structure-based drug discovery
Hubbard, R. E. (2008) · Journal of Synchrotron Radiation · doi:10.1107/s090904950705666x · Cited by 55
Miller, M. J., Foy, K. C., & Kaumaya, P. T. P. (2013) · PubMed · Cited by 54
Fragment-based ligand discovery
Fischer, M. M., & Hubbard, R. E. (2009) · Molecular Interventions · doi:10.1124/mi.9.1.7 · Cited by 52
Tomlinson, I. M. (2004) · Nature Biotechnology · doi:10.1038/nbt0504-521 · Cited by 51
S100A10 as a novel biomarker in colorectal cancer
Shang, J., Zhang, Z., Song, W., Zhou, B., Zhang, Y., Li, G., & Qiu, S. (2013) · Tumor Biology · doi:10.1007/s13277-013-0962-1 · Cited by 46
Boettcher, A., Rüdisser, S., Erbel, P. J. A., Vinzenz, D., Schiering, N., Hassiepen, U., Rigollier, P., Mayr, L. M., & Woelcke, J. (2010) · SLAS DISCOVERY · doi:10.1177/1087057110380455 · Cited by 44
Tan, T.-T., & White, E. P. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-1-4020-6554-5_5 · Cited by 43
Dastjerdi, K., Tabar, G. H., Dehghani, H., & Haghparast, A. (2011) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.36 · Cited by 42
Corradi, V., Mancini, M., Santucci, M. A., Carlomagno, T., Sanfelice, D., Mori, M., Vignaroli, G., Falchi, F., Manetti, F., Radi, M., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.09.011 · Cited by 41
Rini, B. I., Kar, S., & Kirkpatrick, P. N. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2382 · Cited by 41
Reddy, T. R. K., Li, C., Fischer, P. M., & Dekker, L. V. (2012) · ChemMedChem · doi:10.1002/cmdc.201200107 · Cited by 40
Design of Libraries Targeting Protein–Protein Interfaces
Fry, D. C., Huang, K., Lello, P. D., Mohr, P., Müller, K., So, S., Harada, T., Ståhl, M., Vu, B. T., & Mauser, H. (2013) · ChemMedChem · doi:10.1002/cmdc.201200540 · Cited by 35
Novel Therapeutic Modalities to Address Nondrugable Protein Interaction Targets
Souza, E. B. D., Cload, S. T., Pendergrast, P. S., & Sah, D. W. Y. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.115 · Cited by 35
Glanzer, J. G., Carnes, K. A., Soto, P., Liu, S., Parkhurst, L. J., & Oakley, G. G. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1291 · Cited by 33
Bcl-2 Family Proteins as Therapeutic Targets
Czabotar, P. E., & Lessène, G. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210793292429 · Cited by 32
Aptamers: from bench side research towards patented molecules with therapeutic applications
Majumder, P., Gomes, K. N., & Ulrich, H. (2009) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770903313746 · Cited by 31
Discovery of Protein–Protein Interaction Inhibitors of Replication Protein A
Patrone, J. D., Kennedy, J. P., Frank, A. O., Feldkamp, M. D., Vangamudi, B., Pelz, N. F., Rossanese, O. W., Waterson, A. G., Chazin, W., & Fesik, S. W. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400032y · Cited by 31
Fragment-based lead discovery: challenges and opportunities
Sun, C. C., Petros, A. M., & Hajduk, P. J. (2011) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-011-9451-z · Cited by 30
Using Fragment-Based Technologies to Target Protein-Protein Interactions
Bower, J. F., & Pannifer, A. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802651689 · Cited by 29
Thomas, C. E., & Will, Y. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.651122 · Cited by 29
Crystallographic Fragment Screening
Badger, J. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-520-6_7 · Cited by 26
Inhibitors of protein–protein interactions: New methodologies to tackle this challenge
Silvian, L. F., Enyedy, I. J., & Kumaravel, G. (2012) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2012.10.004 · Cited by 25
Can emerging drug classes improve R&D productivity?
Meier, C., Cairns‐Smith, S., & Schulze, U. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.05.006 · Cited by 17
Advances in therapy: eribulin improves survival for metastatic breast cancer
Morris, P. G. (2010) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32833ed62e · Cited by 16
Virtual screening of low molecular weight mushrooms compounds as potential Mdm2 inhibitors
Froufe, H. J. C., Abreu, R. M. V., & Ferreira, I. C. F. R. (2012) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756366.2012.658787 · Cited by 15
BcL-xL Conformational Changes upon Fragment Binding Revealed by NMR
Aguirre, C., ten Brink, T., Walker, O., Guillière, F., Davesne, D., & Krimm, I. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064400 · Cited by 12
Roy, S., Ghosh, P., Roy, N. S., Mazumder, A., Roy, K., Manna, A. K., Mallick, S., & Ahmed, I. (2012) · Current Chemical Biology · doi:10.2174/187231312801254732 · Cited by 7
Targeting Cancer Using Fragment Based Drug Discovery
Turnbull, A. P., & Boyd, S. M. (2012) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152012798764660 · Cited by 6
New drug therapies for advanced renal cell carcinoma
Gore, M. E., Harrison, M., & Montes, A. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.1.57 · Cited by 4
Dos-Santos, O., Lagarde, P., Pérot, G., Chibon, F., Ratet, N., Flamand, O., & Debüssche, L. (2012) · European Journal of Cancer · doi:10.1016/s0959-8049(12)71633-7 · Cited by 3
High-Throughput Screening in Industry
Boisclair, M. D., Egan, D. A., Huberman, K., & Infantino, R. (2004) · Anticancer Drug Development Guide · doi:10.1007/978-1-59259-739-0_2
Research works printed but not linked: 1
- Ratnaparkhi, M. P., Chaudhari, S. P. & Pandya, V. A. Peptides and proteins in pharmaceuticals. Int. J. Curr. Pharm. Res. 3, 1–9 (2011).
Cited by
Lu, H., Zhou, Q., He, J., Jiang, Z., Peng, C., Tong, R., & Shi, J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00315-3 · Cited by 891
“Such a modulator may face pharmacokinetic issues due to its large molecular weight and poor solubility.(8) Therefore, the small molecule modulator is more suitable for the tight and narrow PPI interface.”
BackgroundTherapeutic Targeting of Long Non-Coding RNAs in Cancer
Arun, G., Diermeier, S. D., & Spector, D. L. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.01.001 · Cited by 611
Overcoming cancer therapeutic bottleneck by drug repurposing
Zhang, Z., Zhou, L., Xie, N., Nice, E. C., Zhang, T., Cui, Y., & Huang, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00213-8 · Cited by 516
“High-quality structural data of known receptor targets involved in cancer can accurately predict specific drug targets using drug libraries.(451,452) As an exemplar, bromovinyldeoxyuridine (BVDU) is a thymidine analog used for the treatment of herpes zoster infection, which interacts with viral thymidine kinase using…”
BackgroundDrugging the undruggables: exploring the ubiquitin system for drug development
Huang, X., & Dixit, V. M. (2016) · Cell Research · doi:10.1038/cr.2016.31 · Cited by 427
Delineating the role of cooperativity in the design of potent PROTACs for BTK
Zorba, A., Nguyen, C., Xu, Y., Starr, J., Borzilleri, K., Smith, J., Zhu, H., Farley, K. A., Ding, W., Schiemer, J., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1803662115 · Cited by 419
“This breadth has led to tremendous excitement in the drug development field, particularly with regard to targeting the “undruggable” proteome (15).”
Background
Metadata
- Authors
- Nero, T. L., Morton, C. J., Holien, J. K., Wielens, J., & Parker, M. W.
- Affiliations
- Australian Cancer Research Foundation (AU)
- The University of Melbourne (AU)
- Corresponding author
- Parker, Michael W.
- Venue
- Nature Reviews Cancer
- Published
- 2014-03-13
- Volume
- 14
- Issue
- 4
- Pages
- 248-262
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2003516462
- Cited by
- 312
- References
- 161
- Citations by year
- 2026: 11 · 2025: 19 · 2024: 35 · 2023: 29 · 2022: 15 · 2021: 19 · 2020: 29 · 2019: 19 · 2018: 26 · 2017: 24 · 2016: 34 · 2015: 37 · 2014: 15
- FWCI
- 3.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- protein-protein interaction, oncoprotein, small molecule modulators, drug discovery, undruggable targets, protein-protein interaction surfaces, cancer drug targets
- MeSH terms
- Animals, Antineoplastic Agents, Binding Sites, Drug Screening Assays, Antitumor, Humans, Neoplasms, Protein Binding, Surface Properties, Oncogene Proteins, Protein Interaction Domains and Motifs, Protein Interaction Maps, Molecular Docking Simulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.